NCT07410481 Trial of Acceptance and Mindfulness-based Exposure Therapy (AMBET) and Present Centered Therapy (PCT)
| NCT ID | NCT07410481 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Columbia University |
| Condition | PTSD - Post Traumatic Stress Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-03-31 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-03-31 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a new therapy called Acceptance- and Mindfulness-Based Exposure Therapy (AMBET) helps treat post-traumatic stress disorder (PTSD) in people who survived a cardiac arrest. This study will compare AMBET to another psychotherapy treatment called Present Centered Therapy (PCT) to see which therapy is more effective in treating PTSD. The main questions it aims to answer are: Does AMBET reduce PTSD symptoms in survivors of cardiac arrest? How do the benefits of AMBET compare to PCT? Participants will: * Be randomly assigned to receive either AMBET or PCT * Attend 12 hours of individual psychotherapy sessions over about 12 weeks * Complete short weekly surveys about their mood and behaviors online * Wear a Fitbit device to track sleep and activity during the study * Do brief homework assignments between sessions
Eligibility Criteria
Inclusion Criteria: 1. Between 18 and 81 years old at the time of consent 2. Fluency in English 3. Medical history of cardiac arrest \>3 months ago 4. Clinically elevated PTSD symptoms (Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) score ≥25) 5. U.S. Resident Exclusion Criteria: 1. Lifetime history of primary psychotic or bipolar disorders 2. Current substance use disorder (moderate or severe in the past 6 months) 3. Active suicidal ideation with some intent to act in past 12 months, and/or suicide attempt in past 24 months 4. Substantial cognitive impairment (Mini Mental Status Exam (MMSE) score \<25) 5. Initiation of new psychotropic medication \<3 months ago 6. Non-cardiac etiology of CA (drowning, bleeding, trauma, drug overdose, etc) 7. Terminal illness with life expectancy \<1 year 8. Concurrent psychotherapy for PTSD
Contact & Investigator
Yuval Neria, PhD
PRINCIPAL INVESTIGATOR
Columbia University
Frequently Asked Questions
Who can join the NCT07410481 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 81 Years, studying PTSD - Post Traumatic Stress Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07410481 currently recruiting?
Yes, NCT07410481 is actively recruiting participants. Contact the research team at ny126@cumc.columbia.edu for enrollment information.
Where is the NCT07410481 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT07410481 clinical trial?
NCT07410481 is sponsored by Columbia University. The principal investigator is Yuval Neria, PhD at Columbia University. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.